ZHBIO(SZ:300653)2024-11-28 01:23Financial Performance - In the first three quarters of 2024, the company achieved operating revenue of 291 million CNY, a decrease of 9.46% year-on-year [2] - For the third quarter alone, the operating revenue was 933.24 million CNY, reflecting a year-on-year decline of 4.06%, although the decline has narrowed [2] Market Competition and Product Strategy - The company is optimizing marketing strategies for oral products in the implant sector and actively expanding market share [2] - New product development is ongoing, with the registration application for calcium silicate bio-ceramic bone repair materials accepted, and the biological repair membrane in the registration phase [2] Active Biological Bone Product Development - The active biological bone product was officially launched in early 2024, with network access completed in all 31 provinces, and the number of hospital admissions is steadily increasing [3] - The company is conducting nationwide招商 (investment promotion) and brand-building activities to enhance market recognition and sales volume [3] Pricing and Procurement Policies - The Tianjin Medical Procurement Center has issued guidelines that may affect the pricing of bone-forming proteins and related products, with the company committed to tracking these policies [3] - The absorbable hard brain (spinal) membrane patch has been selected in all 24 provinces where volume-based procurement has been implemented since 2020 [3] Impact of Collective Procurement - Collective procurement has led to a decrease in the selling price of brain membrane products but has also stimulated sales growth [3] - In 2023, the company successfully won bids in the Liaoning and Shaanxi alliances, with short-term revenue fluctuations in the first half of 2024 attributed to the implementation of these procurement policies [3]